Key result
ISAR-WAVE trial will test if intravascular lithotripsy outperforms other calcium-modifying techniques for severely calcified lesions.
Why the study?
Randomized trials powered for clinical outcomes evaluating the relative merits of intravascular lithotripsy compared to other calcium-modifying techniques in patients with severely calcified lesions are lacking.
Does intravascular lithotripsy improve clinical outcomes compared to other calcium-modifying techniques in patients with de novo severely calcified coronary lesions?
RCT (n=666)
single-blind
randomized
Yes
Does intravascular lithotripsy improve clinical outcomes compared to other calcium-modifying techniques in patients with de novo severely calcified coronary lesions?
The ISAR-WAVE trial is designed to determine if intravascular lithotripsy is superior to other calcium-modifying techniques for treating severely calcified coronary lesions.
Answers are grounded in this paper and cite their sources.
ISAR-WAVE RCT will test intravascular lithotripsy superiority; extends randomized evidence for calcium modification in calcified lesions.
BACKGROUND: Percutaneous coronary intervention of severely calcified lesions is limited by inadequate stent expansion and poor clinical outcomes. Over the past decade, several devices and techniques have been developed for calcium modification and lesion preparation. Intravascular lithotripsy (IVL) is a novel tool in this context. Although numerous observational studies have been reported on this technique, randomized trials powered for clinical outcomes on the relative merits of IVL in patients with severely calcified lesions are lacking. STUDY DESIGN AND OBJECTIVES: The ISAR-WAVE trial is a multicenter, prospective, randomized, single-blind controlled trial. The aim is to test whether IVL is superior to other calcium-modifying techniques (modified or super high-pressure balloon and atheroablative devices) in de novo severely calcified coronary lesions. The study is planned to enroll 666 patients. The primary endpoint is the composite of major cardiac and cerebrovascular adverse events defined as death, nonfatal myocardial infarction, nonfatal stroke and clinically indicated target vessel revascularization at 12 months. In addition to the individual components of the primary endpoint, secondary endpoints include also safety, quality of life and cost-effectiveness measures. CONCLUSIONS: ISAR-WAVE is a multicenter, randomized trial designed to test the hypothesis that a strategy of IVL confers superior clinical performance compared to other calcium-modifying techniques in patients undergoing percutaneous intervention for a de novo severely calcified coronary artery lesion. TRIAL REGISTRATION: ClilicalTrial.gov, NCT06369142.
No takes yet. Share an insight, caveat, or question.
Cassese et al. (2024) conducted an RCT in de novo severely calcified coronary lesions (n=666). Intravascular lithotripsy (IVL) vs. other calcium-modifying techniques (modified or super high-pressure balloon and atheroablative devices) was evaluated on composite of major cardiac and cerebrovascular adverse events defined as death, nonfatal myocardial infarction, nonfatal stroke and clinically indicated target vessel revascularization at 12 months. The ISAR-WAVE trial is designed to randomize 666 patients to determine if intravascular lithotripsy is superior to other calcium-modifying techniques for severely calcified coronary lesions.
Synapse has enriched 10 related papers. Consider them for comparative context: